NasdaqGS - Nasdaq Real Time Price • USD
Aclaris Therapeutics, Inc. (ACRS)
As of 2:09 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 7 |
| Avg. Estimate | -0.29 | -0.25 | -0.99 | -0.82 |
| Low Estimate | -0.37 | -0.35 | -1.35 | -1.49 |
| High Estimate | -0.08 | -0.08 | -0.32 | -0.31 |
| Year Ago EPS | -0.42 | -0.42 | -1.27 | -0.99 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | 1.37M | 1.37M | 5.58M | 6M |
| Low Estimate | 570k | 570k | 2.26M | 2.26M |
| High Estimate | 1.87M | 1.87M | 7.48M | 7.8M |
| Year Ago Sales | -- | 1.9M | 31.25M | 5.58M |
| Sales Growth (year/est) | -- | -27.90% | -82.10% | 7.50% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.44 | -0.45 | -0.48 | -0.34 |
| EPS Actual | -0.42 | -0.42 | -0.41 | -0.02 |
| Difference | 0.02 | 0.03 | 0.07 | 0.32 |
| Surprise % | 4.50% | 6.70% | 14.60% | 94.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.29 | -0.25 | -0.99 | -0.82 |
| 7 Days Ago | -0.29 | -0.25 | -0.99 | -0.82 |
| 30 Days Ago | -0.29 | -0.25 | -0.99 | -0.82 |
| 60 Days Ago | -0.31 | -0.28 | -1.17 | -1.21 |
| 90 Days Ago | -0.31 | -0.28 | -1.2 | -1.21 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ACRS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 31.00% | -- | -- | 1.50% |
| Next Qtr. | 40.50% | -- | -- | 11.40% |
| Current Year | 22.00% | -- | -- | 5.20% |
| Next Year | 17.20% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 74.40% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Downgrade | HC Wainwright & Co.: Buy to Neutral | 1/22/2024 |
| Downgrade | BTIG: Buy to Neutral | 1/11/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 12/29/2023 |
| Maintains | Stifel: Hold to Hold | 12/18/2023 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 11/14/2023 |
| Downgrade | Cantor Fitzgerald: Overweight to Neutral | 11/14/2023 |
Related Tickers
CNTG Centogene N.V.
0.4408
-4.38%
BDSX Biodesix, Inc.
1.2423
-1.40%
ENZ Enzo Biochem, Inc.
1.0500
-0.94%
E08A.F Exagen Inc.
1.2600
-2.33%
ANPCF ANGLE plc
0.1964
0.00%
BIAF bioAffinity Technologies, Inc.
2.4500
0.00%
ANPCY ANGLE plc
1.8900
0.00%
DRIO DarioHealth Corp.
1.4600
-2.67%
MVF.AX Monash IVF Group Limited
1.5100
-0.33%
HLS.AX Healius Limited
1.2500
-1.19%